Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. - Wikidata - awgldk - TriplyDB

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

http://www.wikidata.org/entity/Q44917839

about

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Diagnosis and treatment of deep-vein thrombosis New anticoagulants for the prevention and treatment of venous thromboembolism Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art Deep Venous Thrombosis: An Interventionalist's Approach Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism Fondaparinux in the management of patients with ST-elevation acute myocardial infarction Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies Deep vein thrombosis: current status and nanotechnology advances.Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Venous thromboembolism: classification, risk factors, diagnosis, and management.Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism.Fondaparinux: a potential new therapy for HIT.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin The role of ximelagatran in the treatment of venous thromboembolism.New anticoagulants: anti IIa vs anti Xa--is one better?Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.Heparin-induced thrombocytopenia: treatment options and special considerations.Latest medical treatment strategies for venous thromboembolism.Current concepts review: venous thromboembolic disease in foot and ankle surgery.Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Severe bleeding secondary to misuse of fondaparinux: a case report.Update on heparin: what do we need to know?[Treatment of venous thromboembolism].Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Fondaparinux: does it cause HIT? Can it treat HIT?An overview of heparin-induced thrombocytopenia.Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach Fondaparinux-associated heparin-induced thrombocytopenia

P2860

Q24193871-6F70A7FC-8DBD-42F7-A6A5-A5F9D3AFD3EA Q24201186-B676AE93-8315-4933-8973-F36DBCB9504C Q24234155-3992BD8F-B4D7-4395-A095-F4E7D6BF5308 Q24235193-377AC77C-0D6F-4D74-BB2E-4BFC5500318D Q24236443-A139A11F-B6EA-41DD-A3BD-A4F64FDF8085 Q24242243-0290966E-5230-4664-A2FF-D92AF3546BC8 Q24632951-1D398D5F-8B07-4D9D-96A5-173D2D8D5DE2 Q24633053-D07E1420-12AD-40C3-8F46-C1341A2BDDEE Q24673847-292A387C-458D-4F0E-A11E-B7AB66CDB5A9 Q24681351-949CE91C-4370-4991-ACCD-D5FDB3473184 Q26776112-922E591F-A88B-48B9-B551-F755854BF3B3 Q26827598-95D2FB42-9933-49D0-90CB-98335F7EC168 Q27008491-961013E3-33EF-4CE2-A2C5-C5FF6E7447D7 Q28079081-165AF153-52BE-412D-8A40-61997E1114EB Q28219415-F30EB842-3CB3-424E-BF11-DD7ACB1E71C0 Q28469258-82F8F241-7A2A-4090-8116-1EBCBFAE79B9 Q30369732-C1FD984C-AE0F-4924-8A4E-9F9CAF92BC28 Q30402038-1CF3007C-575F-4C9B-928E-8D470DCF1505 Q30472938-7745478C-1721-40DE-9683-018ED271D476 Q33156769-5A6599BA-BF42-4EDF-889E-B56C5B693FE2 Q33367708-2DE28384-E117-48B2-8D92-CD55D0BEDDE2 Q33367978-E038E041-7B65-4F71-9E9D-36B2B8C1B432 Q33369274-307AAFFF-AC20-4D29-851E-0D5A845A4F9B Q33370261-E6D8834C-0D26-4B32-93F4-0B07946044D7 Q33372266-C022AAD5-2E8E-4160-8FA5-C6FDA722ABF2 Q33373419-CCEEACA9-D3FA-4140-9D44-96D0E3525214 Q33374658-FBE8A885-1910-4D9C-A7B0-E1A475C56E85 Q33375535-EB8E5AC8-AFE6-4093-9E8E-FF1B3B69741C Q33377443-24B2AF53-46AC-4DC5-AE15-4721A25E16E1 Q33380179-A6938F9B-6004-4E96-AA25-D9E1A8C3F88A Q33380863-EDEBDD69-E5B9-4CEC-A5EE-14DA64AED24E Q33381801-315F6BFD-23C7-4838-B3F3-33EF66B05E75 Q33385457-18D0AFAB-2E13-432A-8806-2188E22A8C0C Q33386920-657F3D7D-5039-4D2D-9B7E-6A878C214B9A Q33387992-ACCEF25B-B81E-4E4F-90B5-15AA0F799605 Q33389966-E02E0AF5-C4DA-41A5-A63C-E8B6E42D9197 Q33392864-CB74F85E-B7F2-4FB8-94E0-9A767D0BE836 Q33394986-DEB1EA1D-9FF7-4A28-8AEF-60276A3754AA Q33396243-50A79D31-1A6B-4E2B-AC61-55E21839556F Q33399335-A37E32AF-731F-4606-9749-94299CADBBE5

P2860

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

http://www.wikidata.org/entity/Q44917839

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@en

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@nl

type

label

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@en

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@nl

prefLabel

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@en

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@nl

P1433

Q44917839-3A919633-E076-4DDF-BAD8-D326B168AA90

P1476

Q44917839-F2F84F27-784B-4FA4-8911-D4EF3440CE6B

P2093

Q44917839-0F483BD7-7C72-4DEC-9295-D8B6B44FE218

Q44917839-1413437D-D167-4CEE-9ADE-642BAAB8E202

Q44917839-1929011E-7C04-4694-A803-64DF5464612F

Q44917839-37A84946-70DA-47CD-A04E-FCF3A407B469

Q44917839-3D9EF9AD-A21C-4E7A-85B5-03C240551684

Q44917839-4DA53D8F-F4F5-4DCF-9916-9EBA65ACBC9E

Q44917839-5D274ED8-E4F8-470E-8033-E454FE7DDB6F

Q44917839-714B298F-3CD8-43ED-A5BE-5C549043493F

Q44917839-B3D70D38-1524-45EA-A27B-9760C8B3B9BA

Q44917839-B4FF331E-28D8-4AA0-81DE-656A9F5C3A59

P304

Q44917839-5C895205-364E-4109-9636-B1698939EE1C

P31

Q44917839-FF69576F-CF09-4540-A263-10D2FD33E79F

P356

Q44917839-5DEF14E8-9CD6-48C8-A67C-677402CF343C

P407

Q44917839-25BBF644-24AD-4EB4-A63C-3A3C6DF4F54B

P433

Q44917839-72BD20CF-1A14-49F3-81B5-7220DF01E5EE

P478

Q44917839-71EB595A-DE4B-432C-B1E3-D98D4661838A

P577

Q44917839-B004B64A-9162-448C-8D83-0CA02C4F2EA4

P698

Q44917839-6E0E7559-D810-4E8C-B220-BBC26E44E9F4

P921

Q44917839-B99C979F-0BAC-4391-97D7-25E649467AAA

P356

0003-4819-140-11-200406010-00007

P1433

Annals of Internal Medicine

P1476

Fondaparinux or enoxaparin for ...... hrombosis: a randomized trial.

@en

P2093

Alexander Gallus

http://www.w3.org/2001/XMLSchema#string

Annelise E M Segers

http://www.w3.org/2001/XMLSchema#string

Anthonie W A Lensing

http://www.w3.org/2001/XMLSchema#string

Bruce L Davidson

http://www.w3.org/2001/XMLSchema#string

Franco Piovella

http://www.w3.org/2001/XMLSchema#string

Gary Raskob

http://www.w3.org/2001/XMLSchema#string

Harry R Büller

http://www.w3.org/2001/XMLSchema#string

Hervé Decousus

http://www.w3.org/2001/XMLSchema#string

Martin H Prins

http://www.w3.org/2001/XMLSchema#string

Matisse Investigators

http://www.w3.org/2001/XMLSchema#string

P304

867-873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-140-11-200406010-00007

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15172900

http://www.w3.org/2001/XMLSchema#string

P921